Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trial
Bruno François(Inserm), Pierre‐François Laterre(Cliniques Universitaires Saint-Luc), Marc Derive, Aurélie Olivier, Jean Jacques Garaud, Simon Lambden(University of Cambridge), Valérie Cuvier, Margarita Salcedo‐Magguilli, Stephan Witte(MerLion Pharma (Germany)), Mitchell M. Levy(Brown University), Jean‐Marie Grouin(Université de Rouen Normandie), Sébastien Gibot(Centre Hospitalier Régional et Universitaire de Nancy)
Cited by 20
Related Papers
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
|JAMA|2016|28.1k
Surviving Sepsis Campaign
|Critical Care Medicine|2013|9.7k
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
|Intensive Care Medicine|2013|7.3k
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016
|Intensive Care Medicine|2017|6.8k
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
|New England Journal of Medicine|2001|6.1k